Physician profile
Ayesha Ebrahim
NPI 1831144609
$3,254.05
in general payments reported to CMS, 2019-2025
42 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.47 · 2020: $284 · 2021: $778 · 2022: $229 · 2023: $635 · 2024: $707 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $377.66 | 2021-2025 | Invega Sustenna, Spravato |
| Idorsia Pharmaceuticals US INC | $283.22 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $253.88 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $180.28 | 2020-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.56 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $140.15 | 2019-2021 | |
| Medtronic, INC. | $134.53 | 2022-2024 | Minimed 780g |
| Lilly USA, LLC | $131.16 | 2019-2024 | Zepbound |
| Corcept Therapeutics | $125.60 | 2024-2025 | Korlym |
| Tandem Diabetes Care, INC. | $107.44 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $104.35 | 2021-2023 | Ingrezza |
| Insulet Corporation | $92.64 | 2020-2025 | Omnipod |
| Dexcom, INC. | $71.54 | 2020-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.93 | 2019-2023 | Jardiance |
| Abbvie INC. | $68.88 | 2020-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Ebrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.